Cartesian Therapeutics Inc News - RNAC

Cartesian Therapeutics Announces New Employment Inducement Grants

GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with...

Cartesian Therapeutics Announces New Employment Inducement Grant

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the...

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cartesian Therapeutics Inc (RNAC)

Professional-Grade Tools, for Individual Investors.

RNAC News

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

RNAC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cartesian Therapeutics Inc (RNAC) News

Cartesian Therapeutics Inc (RNAC)

Professional-Grade Tools, for Individual Investors.

RNAC News

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

RNAC Discussion

Your Recent History